Police & Firemen s Retirement System of New Jersey Has $2.24 Million Stock Position in Hologic, Inc. $HOLX

Police & Firemen s Retirement System of New Jersey increased its stake in Hologic, Inc. (NASDAQ:HOLX) by 5.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 34,322 shares of the medical equipment provider’s stock after purchasing an additional 1,732 shares during the period. Police & Firemen s Retirement System of New Jersey’s holdings in Hologic were worth $2,236,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of HOLX. Greenleaf Trust increased its holdings in Hologic by 5.1% in the 2nd quarter. Greenleaf Trust now owns 3,579 shares of the medical equipment provider’s stock valued at $233,000 after buying an additional 173 shares during the period. Savant Capital LLC boosted its position in shares of Hologic by 1.2% during the 2nd quarter. Savant Capital LLC now owns 19,606 shares of the medical equipment provider’s stock worth $1,278,000 after acquiring an additional 232 shares in the last quarter. First American Bank increased its stake in Hologic by 0.9% in the second quarter. First American Bank now owns 28,705 shares of the medical equipment provider’s stock valued at $1,870,000 after acquiring an additional 245 shares during the last quarter. Oppenheimer Asset Management Inc. raised its position in Hologic by 1.7% during the second quarter. Oppenheimer Asset Management Inc. now owns 14,788 shares of the medical equipment provider’s stock valued at $964,000 after purchasing an additional 246 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its stake in Hologic by 193.6% during the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 273 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Up 0.1%

Shares of NASDAQ HOLX opened at $74.17 on Thursday. The company has a 50 day simple moving average of $70.24 and a 200 day simple moving average of $66.10. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $80.31. The firm has a market cap of $16.50 billion, a PE ratio of 30.78, a price-to-earnings-growth ratio of 2.54 and a beta of 0.65.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.03. The firm had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.03 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company’s revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the company posted $1.01 EPS. On average, research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Buying and Selling at Hologic

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the firm’s stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the transaction, the chief executive officer directly owned 1,234,624 shares in the company, valued at $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christiana Stamoulis sold 7,402 shares of Hologic stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the completion of the transaction, the director directly owned 47,336 shares in the company, valued at approximately $3,458,841.52. This represents a 13.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.88% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on HOLX shares. UBS Group lifted their price target on Hologic from $65.00 to $70.00 and gave the company a “neutral” rating in a research note on Thursday, July 31st. Morgan Stanley lifted their target price on Hologic from $69.00 to $76.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 11th. BTIG Research reissued a “neutral” rating on shares of Hologic in a research note on Tuesday, October 21st. JPMorgan Chase & Co. restated a “neutral” rating and issued a $78.00 price target on shares of Hologic in a research note on Wednesday, October 22nd. Finally, Evercore ISI set a $78.00 price objective on shares of Hologic and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and thirteen have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $79.77.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.